Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $190

巴克萊銀行維持泰尼特(THC.US)買入評級，上調目標價至190美元

moomoo資訊 · 11/08 19:31 · 評級/大行評級

Barclays analyst Andrew Mok CFA maintains $Tenet Healthcare (THC.US)$ with a buy rating, and adjusts the target price from $171 to $190.

According to TipRanks data, the analyst has a success rate of 42.1% and a total average return of -5.4% over the past year.

AnalystRecentRatingAutoNews_201836_20241108_895a75317c6ce2edded518f023d220daf61922b7_1731144625313520_mm_en

Furthermore, according to the comprehensive report, the opinions of $Tenet Healthcare (THC.US)$'s main analysts recently are as follows:

The outlook for hospitals was exceptionally positive in 2024, and this trend appears set to continue into 2025. There is potential for earnings growth for both HCA and Tenet, provided that the assumptions for organic growth are sensible.
Following Tenet Healthcare's Q3 earnings, revisions to models and detailed earnings assessments for each hospital were noted, with most core adjustments being relatively minor. Changes are primarily driven by the effects of hurricane impacts and updated assumptions regarding Medicaid supplemental payments.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

巴克萊銀行分析師Andrew Mok CFA維持$泰尼特 (THC.US)$買入評級，並將目標價從171美元上調至190美元。

根據TipRanks數據顯示，該分析師近一年總勝率為42.1%，總平均回報率為-5.4%。

AnalystRecentRatingAutoNews_201836_20241108_895a75317c6ce2edded518f023d220daf61922b7_1731144625313520_mm_tc

此外，綜合報道，$泰尼特 (THC.US)$近期主要分析師觀點如下：

2024年，醫院的前景異常樂觀，這種趨勢似乎將持續到2025年。只要有機增長的假設合理，HCA和Tenet都有可能實現盈利增長。
繼Tenet Healthcare公佈第三季度業績之後，注意到對每家醫院的模型和詳細收益評估進行了修訂，大多數核心調整相對較小。變化主要是由颶風影響的影響以及有關醫療補助補充補助金的最新假設推動的。

提示:

TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。

TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。

分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。

總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。更多信息

Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $190

Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $190

風險及免責聲明

聲明